CMMB
Income statement / Annual
Last year (2024), Chemomab Therapeutics Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Chemomab Therapeutics Ltd.'s net income was -$13,945.00.
See Chemomab Therapeutics Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$66,827.00
|
$57,773.00
|
$34,023.00
|
$79,999.00
|
$281,909.00
|
$66,000.00
|
$51,000.00
|
$40,638.00
|
$26,253.00
|
| Gross Profit |
$0.00
|
-$66,827.00
|
-$57,773.00
|
-$34,023.00
|
-$79,999.00
|
-$281,909.00
|
-$66,000.00
|
-$51,000.00
|
-$40,638.00
|
-$26,253.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11,327.00
|
$18.38 M
|
$16.98 M
|
$6.33 M
|
$4.68 M
|
$13.35 M
|
$7.51 M
|
$6.23 M
|
$2.34 M
|
$5.96 M
|
| General & Administrative Expenses |
$3,412.00
|
$7.08 M
|
$11.56 M
|
$6.03 M
|
$1.29 M
|
$960,000.00
|
$374,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.96 M
|
$5.08 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3,412.00
|
$7.08 M
|
$11.56 M
|
$6.03 M
|
$1.29 M
|
$5.98 M
|
$5.46 M
|
$3.11 M
|
$2.25 M
|
$1.14 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$749,000.00
|
$3.35 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14,739.00
|
$25.46 M
|
$28.53 M
|
$12.37 M
|
$5.97 M
|
$19.33 M
|
$12.97 M
|
$9.34 M
|
$4.59 M
|
$7.11 M
|
| Cost And Expenses |
$14,739.00
|
$25.46 M
|
$28.53 M
|
$12.37 M
|
$5.97 M
|
$19.61 M
|
$13.04 M
|
$9.39 M
|
$4.63 M
|
$7.13 M
|
| Interest Income |
$0.00
|
$1.23 M
|
$351,618.00
|
$65.00
|
$19,999.00
|
$393,000.00
|
$0.00
|
$1,000.00
|
$521.00
|
$1,029.54
|
| Interest Expense |
$0.00
|
$0.00
|
$353,000.00
|
$111,076.00
|
$6,000.00
|
$9,000.00
|
$0.00
|
$5,000.00
|
$0.00
|
$14,156.00
|
| Depreciation & Amortization |
$67.00
|
$67,000.00
|
$57,773.00
|
$34,023.00
|
$79,999.00
|
$281,909.00
|
$66,000.00
|
$51,000.00
|
$40,638.00
|
$26,253.00
|
| EBITDA |
-$14,672.00 |
-$25.39 M |
-$28.48 M |
-$12.33 M |
-$5.95 M |
-$26.92 M |
-$13.36 M |
-$9.50 M |
-$4.57 M |
-$7.46 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$794.00
|
$1.24 M
|
$353,000.00
|
-$111,000.00
|
$21,000.00
|
-$7.60 M
|
-$455,515.00
|
-$164,629.00
|
$20,690.00
|
-$367,793.00
|
| Income Before Tax |
-$13,945.00
|
-$24.22 M
|
-$28.18 M
|
-$12.48 M
|
-$5.95 M
|
-$27.21 M
|
-$13.49 M
|
-$9.48 M
|
-$4.60 M
|
-$7.50 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$534,000.00
|
$77,000.00
|
-$21,000.00
|
$1.00
|
$306,000.00
|
$323,000.00
|
$136,241.00
|
-$3.00
|
| Net Income |
-$13,945.00
|
-$24.22 M
|
-$27.65 M
|
-$12.56 M
|
-$5.93 M
|
-$27.21 M
|
-$13.80 M
|
-$9.81 M
|
-$4.73 M
|
-$7.50 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.0009 |
-0.103 |
-0.1215 |
-0.0605 |
-0.315115 |
-0.78999 |
-1.092 |
-10.8655 |
-0.871 |
-1.647 |
| EPS Diluted |
-0.0009 |
-0.103 |
-0.1215 |
-0.0605 |
-0.315115 |
-0.78999 |
-1.092 |
-10.8655 |
-0.871 |
-1.647 |
| Weighted Average Shares Out |
$16.23 M
|
$234.98 M
|
$227.59 M
|
$207.47 M
|
$37.10 M
|
$34.45 M
|
$12.63 M
|
$902,500.00
|
$5.43 M
|
$4.55 M
|
| Weighted Average Shares Out Diluted |
$16.23 M
|
$235.00 M
|
$227.59 M
|
$207.47 M
|
$37.10 M
|
$34.45 M
|
$12.63 M
|
$902,500.00
|
$5.43 M
|
$4.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
